MDG-3010 / Medigene, WuXi AppTec - LARVOL DELTA

Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment (GlobeNewswire) - "Medigene will focus its R&D on generating new TCRs for TCR-guided therapies, and also in advancing its TCR-guided T cell engager (TCR-TCE) MDG3010 program in collaboration with WuXi Biologics. The Company expects to expand its TCR-TCE pipeline through additional partnerships in the near future; The Company will temporarily delay the start of its IND approved, clinic-ready MDG1015 Phase 1 clinical trial while actively seeking partnerships and additional financing options to advance this program into the clinic. In line with the Company’s previous communication, the CTA submission is planned for Q4 2024 to enhance the opportunity for patient recruitment; Medigene will deprioritize further work on all other autologous cell therapy programs including MDG2021...MDG2011 (targeting KRAS G12V with HLA-A*11) and MDG2012. As such, the Company will pause all pre-clinical development work and will actively seek partnerships to advance those programs through pre-clinical stage to IND."

New trial • Pipeline update • Oncology • Solid Tumor